Ascorbate protects liver from metabolic disorder through inhibition of lipogenesis and suppressor of cytokine signaling 3 (SOCS3)

Yingying Xu 1,2, Yuhang Wu 1,2, Yue Xiong 1,2,3, Jiawang Tao 1,2,3, Tingcai Pan 1,2,3, Shenglin Tan 1,2,3, Ge Gao 1,2, Yan Chen 1,2,4,5, Nasir Abbas 1,2,3, Anteneh Getachew 1,2,3, Yuanqi Zhuang 1,2, Kai You 1,2, Fan Yang 1,2,4,5 and Yin-xiong Li 1,2,4,5*

Abstract

Background: Fatty liver is a reversible status, but also an origin stage to develop to other metabolic syndromes, such as diabetes and heart disease that threatens public health worldwide. Ascorbate deficiency is reported to be correlated with increasing risks for metabolic syndromes, but whether ascorbate has a therapeutic effect is unknown. Here, we investigated if ascorbate treatment alone could work on protecting from the development of steatosis and mechanisms beyond.

Methods: Guinea pigs were fed with a chow diet or a high palm oil diet (HPD) respectively. HPD induced animals were administered different concentrations of ascorbate in different time intervals through water. Besides, hepatocyte-like cells derived from human embryonic stem cells and HepG2 cells were treated with palmitic acid (PA) to induce lipid accumulation for molecular mechanism study.

Results: We find that ascorbate rescues HPD and PA induced steatosis and insulin tolerance in vivo and in vitro. We demonstrate that ascorbate changes cellular lipid profiles via inhibits lipogenesis, and inhibits the expression of SOCS3 via STAT3, thus enhances insulin signal transduction. Overexpression of SOCS3 abolishes the ascorbate rescue effects on insulin signal and lipid accumulation in hepatic cells.

Conclusions: Ascorbate ameliorates hepatic steatosis and improves insulin sensitivity through inhibiting lipogenesis and SOCS3.

Keywords: Guinea pig, Lipidomics, Lipogenesis, Insulin signaling, STAT3

Introduction

Metabolic syndrome has become an epidemic case with detrimental effects on public health and is thought to be an origin of many other metabolic diseases. From the known metabolic syndromes, hepatic steatosis and insulin resistance, which are closely related to development of non-alcohol fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2D), are in association with ectopic accumulation [1].

Insulin resistance is a pathological condition in which cells fail to respond to insulin normally. Excess lipid metabolites trigger a number of different serine kinases with subsequent impairments of insulin signaling or prevent activation of Akt2 [2–4], resulting in insulin resistance. Insulin resistance increases releasing of fatty acids from adipose and delivery of glucose as well as fatty acids to liver, inducing de novo lipogenesis and fatty acid esterification in hepatocytes, resulting ectopic lipid accumulation and steatosis [5]. SOCS3, which is a negative
regulator of the JAK/STAT pathway is implicated in hypertriglyceridemia associated with insulin resistance and leptin resistance [6, 7]. Thus, inhibition of SOCS3 is believed to play a central role in metabolic syndrome [8].

Ascorbate is an essential element of organisms due to its capacity of anti-oxidant, anti-inflammation and therapeutic effects for many diseases. It is a coenzyme of many enzymes, including 7α-hydroxylase, which catalyzes the conversion of cholesterol to 7α-hydroxycholesterol [9]. In addition, it is a well-known anti-oxidant, which reduces the content of reactive oxygen species in hepatocyte mitochondria. For a long time, many researches have shown that ascorbate deficiency is correlated to increasing risks for NAFLD and atherosclerosis according to animal models and epidemiological surveys [10–13]. However, further investigations on ascorbate intervention in disease progression have been reporting inconsistent outcomes on animal and human studies [14–17]. Here, we have investigated if ascorbate treatment alone could be of therapeutic value to protect the development of steatosis and mechanisms more than anti-oxidation.

We found that ascorbate ameliorated hepatic steatosis induced by excess saturated fatty acid influx through changing cellular lipid profiles as well as improving insulin sensitivity which was related to inhibition of SOCS3.

Method

Cell culture

Cells were maintained at 37 °C with humidified air and 5% CO₂. HepG2 cells were cultured in DMEM (low glucose; Gbico) supplemented with 10% FBS (Gbico) and 1% NEAA (Hyclone). Cells were changed to be cultured in DMEM without FBS overnight before use. Cell lysate for insulin signaling pathway detection was collected after stimulation with 100 nm insulin for 5-15 min.

Animal assays

Male Hartley guinea pigs of about 8-weeks-old were housed in a controlled environment (12 h daylight cycle), with free access to food and water. Guinea pigs were fed with a chow diet or a HPD contained 15% palm oil (Animal center of Guangdong province). Serum samples were collected after 16 h of fasting. Biochemical parameters of serum were detected by automated analyzer (HITACHI-7020). Body composition was assessed by using a micro computed tomography (CT) scanner (HITACHI). IPGTT assays were performed after 16 h of fasting, and 20% D-glucose solution was injected intraperitoneally (i.p.) with a dose of 2 g/kg weight. ITT assays were performed after 4 h of fasting, and insulin was given i.p. with a dose of 1 IU/kg weight. Glucose content was detected by a glucometer (Roche). Liver and muscle samples for detection of insulin signal transduction were collected after stimulation of 2 IU/kg insulin for 20 min.

Dosage information

Ascorbate (2-Phospho-L-ascorbic acid trisodium salt) was dissolved in water at different concentrations for oral intake ad libitum. The water was prepared freshly every day and guinea pigs administered ascorbate were kept alone in individual cages. Guinea pigs were supplied with 200 mg/kg or 600 mg/kg on average for low ascorbate (LA) and high ascorbate (HA) in reference of report described previously with modify [18]. The human equivalent dose is 36 mg/kg or 108 mg/kg referring to a conversion coefficient 0.18 between guinea pig and human according to body surface area. In consideration of molecular weight of sodium ascorbate we used (322.4 g/mol) and ascorbic acid (177 g/mol), there should be a conversion coefficient (0.55) for the same mole, which is 19.8 mg/kg or 59.4 mg/kg for ascorbic acid.

Reagents

Sodium ascorbate was purchased from sigma (Shanghai, China). Intracellular TG and cholesterol content were detected by an enzyme kit (PPLYGEN, Beijing, China) as per the manufacturer’s detections. Periodic Acid Schiff (PAS) Staining Cells were stained with PAS to examine glycogen storage. Reagents were purchased from Qiangen (Hilden, Germany) and the assay was did as per users’ manuscript. Cell viability was detected by Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) as per the manufacturer’s directions. Oil Red O solution, glucose and glycogen detection kits were all from Sigma (Shanghai, China). Antibodies against IR, phospho-IR ( Tyr1150/1151), AKT, phosphor-AKT (Thr 307, Ser 473), FOXO1, phospho-FOXO1 (Ser256), GSK3β, phospho-GSK3β (Ser9), β-tubulin were purchased from cell signaling technology (Danvers, Massachusetts, USA), β-actin was from Santa Cruz (Dallas, Texas, USA), SOCS3 was from Abcam (Cambridge, UK). Insulin ELISA kit for guinea pigs were from Jiancheng (Nanjin Jiancheng, Nanjin, China).

Molecular cloning

Full length of SOCS3 was cloned from cDNA of HepG2 cells and inserted into a lentivirus vector, pSin. Virus packed in 293 T cells and supernatant contained active virus was collected for infection. Positive cells were screened out by puromycin resistance in a dose of 1.2 μg/ml for HepG2. Primers for PCR or shRNA sequence are submitted as Additional file 1.

Metabolite extraction and lipidomics

Cell samples in chloroform/methanol/water (2/1/1, v/v/v) solution were vortexed for 1 min, and centrifuged at
Ascorbate reduces lipid accumulation induced by PA in hepatic cells

For further study, we then established the hepatic cellular steatosis model in HepG2 cell line that was illustrated by TG measurement and cell viability (Fig. 2a-c). As results above, intracellular lipid accumulation reached peak in HepG2 cells without obvious cell damage when cultured with 0.5 mM PA for 48 h.

In order to dissect the detail rescuing effects of ascorbate, we first analyzed the phenotypic outcomes on HepG2 cells treated with PA and different concentrations of ascorbate for 48 h. In the range of 1.55–2.17 mM, intracellular TG contents were significantly decreased while cell viability was not affected (Fig. 2d, e). The ascorbate rescuing effects were also confirmed on hepatocyte-like-cells derived from human embryonic stem cells H1, and the functions and maturation of these cells were also illustrated (Additional file 1: Figure S2A-D). The ascorbate dose curve assay showed that lower concentration level of ascorbate, initially at 0.31 mM, could ameliorate lipid accumulation by reducing TG content to a half compared to PA treatment alone (Additional file 1: Figure S2E). Consistent with that of liver
Fig. 1 Ascorbate protects against hepatic steatosis and insulin resistance in guinea pigs. a Illustration of animal assay. b Body weight change within 18 weeks (n = 6). c Fat and lean ratio for guinea pigs (n ≥ 5). d TG contents in liver (n = 6). e Representative H&E stained and oil red O stained pictures of liver samples. f ITT assays performed on guinea pigs with/without ascorbate intervention after fasting (n = 6). Area under curve (AUC) was quantified as depicted in column diagram. g IPGTT assays performed on guinea pigs with/without ascorbate intervention after fasting (n = 6). Area under curve (AUC) was quantified as depicted in column diagram. h Insulin content in serum after fasting (n = 6). i Western blotting for insulin signaling pathway in liver (left) and muscle (right). Statistical significance was assessed with one way ANOVA.
tissue in guinea pigs, ascorbate also repaired the insulin signaling defects in vitro on the phosphoryl levels of IR and AKT in HepG2 cells (Fig. 2f).

**Ascorbate disrupts PA-induced hepatic lipid profiles and inhibits lipogenesis**

Further, we performed liquid chromatography-tandem mass spectrometry (LC/MS) scanning assay for a global lipid profiling which showed that levels of saturated fatty acids and unsaturated fatty acids from TG were differentially enriched among groups (Fig. 3a). Ascorbate reduced palmitate (C16:0), palmitoleate (C16:1) and oleic acid (C18:1) levels, which resulted in decreased lipid desaturation index (16:1/16:0 and 18:1/18:0), mainly in cardiolipin (CL) and sphingomyelin (SM) (Fig. 3b-g). We then found that changes of lipid profiles was related to lipogenesis in cells. Sterol regulatory element binding proteins (SREBPs) are transcription factors which play a central role in lipid homeostasis. Both full-length (fl) and active SREBP1 (nSREBP1, n) content was decreased in ascorbate administration group (Fig. 3h). In line with this, the expression level of SREBP1 targeted genes were decreased, particularly *SCD1*, the enzyme essential for the first step of de novo lipogenesis, which contributes to lipid desaturation index, and showed expression pattern in a dose dependent manner (Fig. 3i, j, Additional file 1: Figure S2H). As gene information of guinea pigs wasn’t known completely, we mainly used hepatic cells for gene expression detection.

**Ascorbate repairs insulin signal transduction by inhibiting SOCS3 expression**

SOCS3 is a repressor of insulin signaling pathway and it has been reported that inhibition of SOCS3 ameliorated hepatic steatosis and hypertriglyceridemia. We found that in our model, ascorbate reduced *Socs3* mRNA expression level as well as its protein content in liver tissue (Fig. 4a, b). Consistent with that of liver tissue in guinea pig, expression level of SOCS3 in hepatic cells treated with ascorbate was decreased (Fig. 4d, e, Additional file 1: Figure S2 F, G). It seems ascorbate influenced the

### Table 1 Biochemical index in blood of guinea pig

|                | Chow (n = 6) | HPD (n = 6) | LA (n = 6) | HA (n = 6) |
|----------------|--------------|------------|------------|------------|
| TG (mM)       | 0.66 ± 0.053 | 0.97 ± 0.260 | 0.74 ± 0.196 | 0.66 ± 0.127 |
| TC (mM)       | 2.26 ± 0.094 | 2.73 ± 0.250 | 2.93 ± 0.302 | 2.20 ± 0.561 |
| HDL-C (mM)    | 0.19 ± 0.010 | 0.20 ± 0.019 | 0.25 ± 0.025 | 0.22 ± 0.032 |
| LDL-C (mM)    | 2.09 ± 0.060 | 2.52 ± 0.188 | 2.63 ± 0.215 | 2.02 ± 0.536 |

* TG Triglyceride, TC Total cholesterol, HDL-C High density lipoprotein-cholesterol, LDL-C Low density lipoprotein-cholesterol

---

**Fig. 2** Ascorbate reduces lipid accumulation and repairs insulin signal transduction in hepatic cells. With administration of various concentration of PA for 12 h, HepG2 cells were detected (a) intracellular TG content (n = 4) and (b) CCK8 absorbance for viability (n = 3) respectively. Significance was compared with control. HepG2 cells were treated with 0.5 mM PA for various interval, lysates of cells were collected to detect (c) intracellular TG content (n = 4). Significance was compared with PA group at each time point. HepG2 cells were co-treated with PA and ascorbate for 48 h, detected (d) intracellular TG content (n = 6) and (e) CCK8 absorbance for viability (n = 4). (f) Western blotting for phosphoryl level of proteins involved in insulin signaling pathway. Statistical significance was assessed with one way ANOVA.
Fig. 3 Ascorbate disrupts PA-induced hepatic lipid profiles and inhibits lipogenesis. LC/MS lipid profiling of HepG2 cells under PA exposure with two different ascorbate doses for 48 h, n = 6. a Expression pattern of TG significantly changed among groups. b Intracellular palmitate (C16:0), palmitoleate (C16:1), stearate (C18:0) and oleic acid (C18:1) content. c-g Lipid desaturation indexes for total lipid species, cardiolipin (CL) and sphingomyelin (SM) respectively (16:1/16:0, 18:1/18:0). h Western blotting for SREBP1. i Relative expression level of lipogenesis related genes in HepG2 cells (n = 3). j Western blotting for SCD1. Statistical significance was assessed with one way ANOVA.
expression of SOCS3 on transcriptional level. SOCS3 is a cytokine-inducible protein that can be elicited by IL6 through STATs [19, 20]. We then detected STAT3 content in liver tissue as well as hepatic cells, and found that its phosphorylation level was increased in HPD or PA group while it was reduced in ascorbate treated groups both in vivo and in vitro (Fig. 4c, f). It suggested that ascorbate inhibited SOCS3 through STAT3.

To further confirm whether the effect of ascorbate on repairing insulin signal transduction was related to SOCS3, we overexpressed SOCS3 or EGFP in HepG2 cells (Fig. 4g). We then analyzed the insulin signaling pathway in cells. While overexpressing SOCS3, the ascorbate rescued phosphoryl level of IR and AKT was reduced (Fig. 4h), indicating that effects of ascorbate on insulin signal transduction was at least partially dependent on SOCS3 expression.

**Overexpression of SOCS3 compromise effects of ascorbate on lipogenesis**

SOCS3 was reported to play a central role in metabolism and regulated expression of SREBP1c, which was an important transcriptional factor of lipid synthesis involved genes [21]. Measurement of the intracellular TG content indicated that the EGFP transgenic (EGFP-tg) cell line appeared ascorbate rescuing effects. However, the rescuing effects of ascorbate on lipid accumulation was abolished in the SOCS3-tg cell line (Fig. 5a). We described lipogenesis related genes were differentially changed before. We found that expression level of those genes was...
higher in SOCS3-tg cells compared with that in EGFP-tg cells, and regulation effects of ascorbate were compromised (Fig. 5b, c). This suggests that ascorbate reduced lipid accumulation at least partially through inhibiting SOCS3 expression, and overexpression of SOCS3 compromised this effect of ascorbate.

Discussion

Steatosis refers to abnormal lipid accumulation in cells and the pathological consequence is cellular degeneration. It is reported PA exposure brings stress on lipid metabolism, resulting in abnormal lipogenesis, inflammation, and insulin resistance in multiple tissues and organs [22–24]. Here we use PA or diet with oil rich of PA (Additional file 1: Table S1) to conduct disease model in vitro and in vivo to mimic human lifestyle and find ascorbate ameliorates hepatic steatosis as well as insulin resistance. Collectively, we observed that ascorbate reduced lipid accumulation and improved insulin sensitivity by down-regulating SOCS3 expression in vivo and in vitro.

SOCS3 is implicated in hypertriglyceridemia and functioning as a repressor of insulin signal transduction by inhibiting phosphorylation of IR as well as inducing degradation of IRS [25]. Inhibition of SOCS3 ameliorates hepatic steatosis and hypertriglyceridemia, while knock-out of it in liver enhances lipogenesis in obesogenic milieu in mice as there was increased hypothalamic SOCS3 [26]. Here we showed ascorbate partially inhibited SOCS3 expression and ameliorated hepatic steatosis. SREBP1 preferentially enters nucleus to enhance transcription of genes required for lipogenesis when activated by proteolytic cleavage [27]. Our in vitro assays showed ascorbate reduced SREBP1 content, lipid metabolites related genes, especially SCD1, which initiates lipogenesis by catalyzing the conversion of C16:0 and C18:0 to C16:1 and C18:1, and lipid desaturation index. As it was reported that SOCS3 was involved in regulation of SREBP1. We believe ascorbate reprogrammed lipid profiles via inhibiting lipogenesis through SOCS3. Alterations in lipid composition can influence biological activity such as material exchange as well as cellular signal transduction [28, 29]. The biological meaning of the altered fingerprinting of lipids under the ascorbate administration is worth to be further investigated. SOCS3 is also a lepin resistance inducer, thus leads to increased lipogenesis, obesity and hepatic steatosis [30, 31]. In our animal model, we found no obvious significant difference in lepin content among groups, suggesting there was no lepin resistance.

We pursue the mechanism of ascorbate regulates SOCS3 expression is in relevance to transcriptional regulation. Ascorbate promotes the activity of Tet enzymes and Tet2 is reported to recruit Hdac2 to specifically repress IL-6, which is a well-known inducer of SOCSs family through JAK-STAT signaling [32–35]. However, intracellular and extracellular IL6 contents were rarely detected, we wonder even the regulation activity of ascorbate handling the expression pattern of SOCS3 through IL6. If ascorbate may act as an enzymatic cofactor, there is a tendency that ascorbate or its metabolites might work with protein
kinase involved STAT3 signaling, which should further be investigated.

Ascorbate is well tolerance. Compared to the NIH suggestions that the oral RDA of ascorbate is 75–90 mg a day for a health adult, our animal experiments supplied the ascorbate in drink water with higher dose which has been tested in other published work and proven that those dose region has no toxic effects for guinea pigs. In our experiments, the high dose of ascorbate has weak effects on pH value, and the administered guinea pigs had no damage on kidneys and livers (Additional file 1: Figure S1). As limited of bioavailability, only about 20–30% of ascorbate supplied could be available for utilization in usual when gavage, and intravenous injection (i.v.) might administer lower dose of it and reduce risks for some side effects. The safety of ascorbate has been confirmed in clinical trials which up to 10 mM via i.v. for human [36]. We assume our data may provide a reference for clinical use of ascorbate on metabolic syndromes.

In summary, we find a novel insight that ascorbate prevents hepatic steatosis by inhibiting SOCS3 and improving insulin sensitivity in vitro and in vivo. These findings not only illustrate the cellular basis that ascorbate supplement is beneficial for clinical metabolic syndromes, but also provides a clue to generate reporter cell lines with monitored key target proteins functions for drug screening of metabolic syndromes.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12986-020-0431-y.

Additional file 1: Figure S1. Ascorbate administration did not cause obvious damage in vivo and in vitro. Figure S2. Ascorbate ameliorates lipid accumulation in hepatocyte-like cells. Table S1. Composition of palm oil for diet. Table S2. RT-qPCR primers. Table S3. PCR primers.

Abbreviations

FOXO1: Forkhead box protein O1; GSK3β: Glycogen synthase kinase 3β; HPD: High pail oil diet; ICG: Indocyanine green; IR: Insulin receptor; LC/MS: Liquid chromatography–mass; NAFLD: Nonalcoholic fatty liver disease; PA: Palmitic acid; PAF: Platelet-activating factor; PC: Phosphatidylcholine; PE: Phosphatidylethanolamine; SM: Sphingomyelin; SOCS3: Suppressor of cytokine signaling 3; TG: Triglyceride

Acknowledgements

The authors wish to acknowledge outstanding technical support from Yanli Liu, Ruzhi Wei, Xinrong Ke and Guangdong medical laboratory animal center.

Authors’ contributions

YL, YXu designed research. YXu, YW, YXiong, JT, TP, ST, GG, YC and YZ performed assays. FY contributed new reagents or analytical tools. YXu, YW and YXiong analyzed data. YL, YXu, KY, NA, and AG wrote and edited the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by National Program on Key Basic Research Project (2015CB964700), Guangdong Province Science and Technology Plan (2018A050506070), The National Natural Science Foundation of China (31871379, 31900539), Guangdong Province Science and Technology Plan (2016B030301007, 2015B020230007, 2014B020225004), Guangzhou City Science and Technology Plan (201704020212), Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2018GZRR110105011). The authors declare that they have no conflicts of interest with the contents of this article.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

All animals used and experiment protocols were approved by the Experimental animal ethics committee of Guangdong medical laboratory animal center.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Institute of Public Health, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510000, China. 2Guangdong Provincial Key Laboratory of Biocomputing, GIBH, CAS, Guangzhou 510000, China. 3University of Chinese Academy of Sciences, Beijing 100000, China. 4Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, GIBH, CAS, Guangzhou 510000, China. 5Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou, China.

Received: 17 August 2019 Accepted: 20 January 2020

Published online: 04 March 2020

References

1. Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, Yan QW, Miyoshi H, Mashek DG. The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest. 2011;121:2102–10.
2. Bril F, Barb D, Pontillo-Sanchez P, Biermacki D, Lomonaco R, Suman A, Weber NH, Budd JT, Lupi ME, Cusi K. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology. 2017;65:1132–44.
3. Schenck S, Saberi M, Olesky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118:2992–3002.
4. Samuel VT, Petersen KP, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010;375:2267–77.
5. Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a Nexus of metabolic and hepatic diseases. Cell Metab. 2017;27:22–41.
6. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003;278:13740–6.
7. Bjorbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell. 1998;1:169–25.
8. Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse (vol 101, pg 10422, 2004). Proc Natl Acad Sci U S A. 2005;102:13710–1.
9. Ginter E. Ascorbic acid in cholesterol and bile acid metabolism. Ann N Y Acad Sci. 1975;258:410–21.
10. Asaashi ET, Hofso D, Hjelmøseaht J, Birkeland K, Bohmer T. Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr. 2008;87: 362–9.
11. Wrieden WL, Hannah MK, Bolton-Smith C, Tavendale R, Morrison C, Tunstall-Pedoe H. Plasma vitamin C and food choice in the third Glasgow MONICA population survey. J Epidemiol Community Health. 2000;54:355–60.
12. Mussio G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:909–16.
13. Park JK, Kim MR, Lee HR, Hong IH, Ji AR, Ishigami A, Park SJ, Kim JM, Chung HY, Yoo SE, Jeong KS. Vitamin C deficiency attenuates liver fibrosis by way of up-regulated peroxisome proliferator-activated receptor-gamma expression in senescence marker protein 30 knockout mice. Hepatology. 2010;51:1766–77.

14. Oliveira CP, Gayotto LC, Tatali C, Deila Nina BI, Lima ES, Abdalla DS, Lopasso FP, Laurindo FR, Carrilho FJ. Vitamin C and vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats. Nutr J. 2013;2:9.

15. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:898–90.

16. Wei J, Lei GH, Fu L, Zeng G, Yang T, Peng SF. Association between dietary vitamin C intake and non-alcoholic fatty liver disease: a cross-sectional study among middle-aged and older adults. PLoS One. 2016;11:e0147985.

17. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48:1119–28.

18. Nandi BK, Majumder AK, Subramanian N, Chatterjee IB. Effects of large doses of vitamin C in Guinea pigs and rats. J Nutr. 1973;103:1688–95.

19. Starr R, Willson TA, Vinay EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–21.

20. Nakai T, Narasaki M, Hiata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997;387:924–9.

21. Shibata C, Kishikawa T, Otsuka M, Ohno M, Yoshikawa T, Takata A, Yoshida H, Koke K. Inhibition of microRNA122 decreases SREBP1 expression by modulating suppressor of cytokine signaling 3 expression. Biochem Biophys Res Commun. 2013;438:230–5.

22. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P, Dzamko N, Watt MJ, Wormald S, Holthuis JC, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125–31.

23. Veltri S, Longstaff T, Kavanagh J. Suppressor of cytokine signalling-1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol. 2004;24:5434–46.

24. Sachithanandan N, Farn BC, Finch S, Dmitriko N, Watt MJ, Wormall S, Honeyman J, Galic S, Proietto J, Andrekopoulos S, et al. Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity. Hepatology. 2010;52:1632–42.

25. Honarmand AK, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125–31.

26. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Phase I clinical trial of l-ascorbic acid in advanced malignancy. Ann Oncol. 2008;19:1969–74.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.